Title : CAR T-cell product performance in haematological malignancies before and after marketing authorisation.

Pub. Date : 2020 Feb

PMID : 32007196






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Two CAR T-cell therapies, tisagenlecleucel and axicabtagene ciloleucel, have been approved in Europe and the USA, as well as several other countries, for the treatment of leukaemia and lymphoma. axicabtagene ciloleucel nuclear receptor subfamily 1 group I member 3 Homo sapiens